Financial Performance - Net loss for Q2 FY2025 was $15.7 million, compared to a net loss of $13.9 million for the same period last year[5]. - The company reported a basic and diluted net loss per common share of $0.22 for Q2 FY2025, compared to $0.27 for the same period last year[12]. - Total operating expenses for Q2 FY2025 were $17.1 million, compared to $15.2 million for the same period last year[12]. Cash and Equity - Cash, cash equivalents, and investments in marketable securities totaled $105.3 million as of December 31, 2024, down from $127.1 million as of June 30, 2024[3]. - Total stockholders' equity decreased to $99.6 million as of December 31, 2024, down from $121.0 million as of June 30, 2024[12]. Research and Development - Research and development expenses increased to $12.6 million for Q2 FY2025, compared to $12.0 million for the same period last year, primarily due to higher clinical trial activities and personnel-related expenses[4]. - The company anticipates beginning a Phase 3 registrational study for ersodetug in patients with tumor HI in the first half of 2025, with topline results expected in the second half of 2026[8]. - An interim analysis of the sunRIZE study is planned for this quarter, with topline results expected in Q4 2025[8]. Regulatory Developments - The FDA granted Breakthrough Therapy Designation to ersodetug for congenital hyperinsulinism, with enrollment of U.S. participants expected in Q2 2025[2]. Administrative Expenses - General and administrative expenses rose to $4.5 million for Q2 FY2025, up from $3.2 million in the same period last year, driven by increased professional fees and headcount[5].
Rezolute(RZLT) - 2025 Q2 - Quarterly Results